What SEC filings does Corcept Therapeutics Incorporated submit to the SEC?

Corcept Therapeutics Incorporated (CORT) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about CORT?

A Form 4 for CORT discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Corcept Therapeutics Incorporated?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for CORT?

The 10-K is Corcept Therapeutics Incorporated's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all CORT SEC filings directly on EDGAR?

You can view all historical Corcept Therapeutics Incorporated filings on the SEC EDGAR company page for CORT. Each filing card on this page links directly to the original SEC document.

How often does Corcept Therapeutics Incorporated file with the SEC?

Corcept Therapeutics Incorporated files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling CORT shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

CORT SEC Filing News — Corcept Therapeutics Incorporated

Latest SEC filings for Corcept Therapeutics Incorporated (CORT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-16.

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.…

Sector: Healthcare Industry: Biotechnology Market Cap: $12.1B CIK: 1088856

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for CORT currently lean bearish. Of the 20 filing records displayed, 9 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

CORT Filing Activity Snapshot 2026-09-03 — 2026-10-16

Insider Transactions (Form 4)

0 buys vs 9 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$6.46M

Vieira Roberto Wandenkolk (President, Oncology) · 2026-09-03

58,333 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 16 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 16 filings in this group are Form 4s for Corcept Therapeutics Incorporated.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 16 insider filings shown, the breakdown is 9 open-market sale, 5 compensation award, 1 option exercise and 1 gift. 9 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×9: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×5: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Gift ×1: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Form 4 Open-market sale Insider Selling 2026-10-16

CORT insider WILSON JAMES N (Director) sold 10,000 shares (~$1.15M)

WILSON JAMES N, listed as Director at CORCEPT THERAPEUTICS INC, reported an open-market sale of 10,000 CORT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	6,654	$114.48	$761.7K
`S`	Open-market sale	3,046	$115.39	$351.5K
`S`	Open-market sale	300	$116.30	$34.9K

Filing: Form 4 (Insider Transaction) Insider: WILSON JAMES N (Director) Shares: 10,000 Est. Value: $1.15M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-05

CORT insider Vieira Roberto Wandenkolk (President, Oncology) sold 8,333 shares (~$967.4K)

Vieira Roberto Wandenkolk, listed as President, Oncology at CORCEPT THERAPEUTICS INC, reported an open-market sale of 8,333 CORT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	8,333	$21.63	$180.2K
`S`	Open-market sale	1,100	$114.52	$126.0K
`S`	Open-market sale	2,086	$115.73	$241.4K
`S`	Open-market sale	5,147	$116.58	$600.1K
`M`	Option exercise derivative · Stock option (right to buy)	8,333	—	—

Filing: Form 4 (Insider Transaction) Insider: Vieira Roberto Wandenkolk (President, Oncology) Shares: 8,333 Est. Value: $967.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-05

CORT insider Lyon Joseph Douglas (See Remarks) sold 10,000 shares (~$1.16M)

Lyon Joseph Douglas, listed as See Remarks at CORCEPT THERAPEUTICS INC, reported an open-market sale of 10,000 CORT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	810	$13.56	$11.0K
`S`	Open-market sale	810	$115.40	$93.5K
`M`	Option exercise	3,357	$13.56	$45.5K
`M`	Option exercise	5,833	$19.26	$112.3K
`S`	Open-market sale	4,446	$115.70	$514.4K
`S`	Open-market sale	4,744	$116.54	$552.9K
`M`	Option exercise derivative · Stock option (right to buy)	810	—	—
`M`	Option exercise derivative · Stock option (right to buy)	3,357	—	—
`M`	Option exercise derivative · Stock option (right to buy)	5,833	—	—

Filing: Form 4 (Insider Transaction) Insider: Lyon Joseph Douglas (See Remarks) Shares: 10,000 Est. Value: $1.16M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-05

CORT insider Maduck Sean (See Remarks) sold 25,000 shares (~$2.91M)

Maduck Sean, listed as See Remarks at CORCEPT THERAPEUTICS INC, reported an open-market sale of 25,000 CORT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	413	$8.27	$3.4K
`S`	Open-market sale	413	$115.54	$47.7K
`M`	Option exercise	24,587	$8.27	$203.3K
`S`	Open-market sale	15,843	$116.12	$1.84M
`S`	Open-market sale	8,744	$116.55	$1.02M
`M`	Option exercise derivative · Stock option (right to buy)	413	—	—
`M`	Option exercise derivative · Stock option (right to buy)	24,587	—	—

Filing: Form 4 (Insider Transaction) Insider: Maduck Sean (See Remarks) Shares: 25,000 Est. Value: $2.91M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-10-05

CORT insider Form 4 filed for equity award, exercise, or tax withholding

Gunn Justin Frederick (See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	100,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Gunn Justin Frederick (See Remarks)

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-09-28

CORT insider Form 4 filed for equity award, exercise, or tax withholding

Robb Gary Charles (Chief Business Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	17,100	—	—
`G`	Gift	5,000	—	—
`G`	Gift	5,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Robb Gary Charles (Chief Business Officer) Shares: 27,100

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-18

CORT insider Vieira Roberto Wandenkolk (President, Oncology) sold 296 shares (~$29.8K)

Vieira Roberto Wandenkolk, listed as President, Oncology at CORCEPT THERAPEUTICS INC, reported an open-market sale of 296 CORT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	296	$100.82	$29.8K

Filing: Form 4 (Insider Transaction) Insider: Vieira Roberto Wandenkolk (President, Oncology) Shares: 296 Est. Value: $29.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-09-18

CORT insider Form 4 filed for equity award, exercise, or tax withholding

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	17,493	$8.27	$144.7K
`M`	Option exercise derivative · Stock option (right to buy)	17,493	—	—

Filing: Form 4 (Insider Transaction) Insider: Robb Gary Charles (Chief Business Officer) Shares: 17,493

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-16

CORT insider Lyon Joseph Douglas (See Remarks) sold 10,000 shares (~$1.13M)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,596	$11.35	$29.5K
`M`	Option exercise	7,404	$13.56	$100.4K
`S`	Open-market sale	7,812	$113.32	$885.3K
`S`	Open-market sale	2,188	$114.12	$249.7K
`M`	Option exercise derivative · Stock option (right to buy)	2,596	—	—
`M`	Option exercise derivative · Stock option (right to buy)	7,404	—	—

Filing: Form 4 (Insider Transaction) Insider: Lyon Joseph Douglas (See Remarks) Shares: 10,000 Est. Value: $1.13M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-16

CORT insider WILSON JAMES N (Director) sold 10,000 shares (~$1.11M)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	6,800	$110.27	$749.8K
`S`	Open-market sale	400	$110.84	$44.3K
`S`	Open-market sale	2,800	$111.70	$312.8K

Filing: Form 4 (Insider Transaction) Insider: WILSON JAMES N (Director) Shares: 10,000 Est. Value: $1.11M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-03

CORT insider Form 4 filed for equity award, exercise, or tax withholding

Guyer William (Chief Development Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	164	$113.38	$18.6K
`A`	Compensation award	164	—	—

Filing: Form 4 (Insider Transaction) Insider: Guyer William (Chief Development Officer) Shares: 328

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-03

CORT insider Maduck Sean (See Remarks) sold 25,000 shares (~$2.86M)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	25,000	$8.27	$206.8K
`S`	Open-market sale	11,730	$113.94	$1.34M
`S`	Open-market sale	10,989	$114.71	$1.26M
`S`	Open-market sale	2,281	$115.61	$263.7K
`A`	Compensation award	150	$113.38	$17.0K
`A`	Compensation award	150	—	—
`F`	Tax withholding on vested shares	117	$113.38	$13.3K
`M`	Option exercise derivative · Stock option (right to buy)	25,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Maduck Sean (See Remarks) Shares: 25,000 Est. Value: $2.86M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-03

CORT insider Form 4 filed for equity award, exercise, or tax withholding

Mokari Atabak (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	138	$113.38	$15.6K
`A`	Compensation award	138	—	—
`F`	Tax withholding on vested shares	102	$113.38	$11.6K

Filing: Form 4 (Insider Transaction) Insider: Mokari Atabak (Chief Financial Officer) Shares: 378

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-03

CORT insider Form 4 filed for equity award, exercise, or tax withholding

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	164	$113.38	$18.6K
`A`	Compensation award	164	—	—
`F`	Tax withholding on vested shares	91	$113.38	$10.3K

Filing: Form 4 (Insider Transaction) Insider: Robb Gary Charles (Chief Business Officer) Shares: 419

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-03

CORT insider Vieira Roberto Wandenkolk (President, Oncology) sold 58,333 shares (~$6.46M)

Vieira Roberto Wandenkolk, listed as President, Oncology at CORCEPT THERAPEUTICS INC, reported an open-market sale of 58,333 CORT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	138	$113.38	$15.6K
`A`	Compensation award	138	—	—
`F`	Tax withholding on vested shares	102	$113.38	$11.6K
`M`	Option exercise	58,333	$21.63	$1.26M
`S`	Open-market sale	23,600	$109.35	$2.58M
`S`	Open-market sale	23,770	$110.70	$2.63M
`S`	Open-market sale	1,537	$111.37	$171.2K
`S`	Open-market sale	974	$112.40	$109.5K
`S`	Open-market sale	1,606	$113.72	$182.6K
`S`	Open-market sale	5,621	$114.58	$644.0K
`S`	Open-market sale	1,225	$115.44	$141.4K
`M`	Option exercise derivative · Stock option (right to buy)	58,333	—	—

Filing: Form 4 (Insider Transaction) Insider: Vieira Roberto Wandenkolk (President, Oncology) Shares: 58,333 Est. Value: $6.46M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-03

CORT insider Form 4 filed for equity award, exercise, or tax withholding

Lyon Joseph Douglas (See Remarks) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	130	$113.38	$14.7K
`A`	Compensation award	130	—	—
`F`	Tax withholding on vested shares	72	$113.38	$8.2K

Filing: Form 4 (Insider Transaction) Insider: Lyon Joseph Douglas (See Remarks) Shares: 332

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Corcept Therapeutics Incorporated has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-01

CORT Form 144 filed for proposed insider sale by Lyon Joseph Douglas (10,000 shares) ~$1.15M

Lyon Joseph Douglas filed a Form 144 with the SEC indicating intent to sell CORT (CORCEPT THERAPEUTICS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Lyon Joseph Douglas Shares: 10,000 Est. Value: $1.15M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-15

CORT Form 144 filed for proposed insider sale by WILSON JAMES N (30,000 shares) ~$3.34M

WILSON JAMES N filed a Form 144 with the SEC indicating intent to sell CORT (CORCEPT THERAPEUTICS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: WILSON JAMES N Shares: 30,000 Est. Value: $3.34M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-14

CORT Form 144 filed for proposed insider sale by Lyon Joseph Douglas (10,000 shares) ~$1.13M

Filing: Form 144 (Proposed Sale Notice) Insider: Lyon Joseph Douglas Shares: 10,000 Est. Value: $1.13M

View on SEC EDGAR → Open Filing Document →

Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for Corcept Therapeutics Incorporated. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-23

CORT filed 8-K — material company event

CORCEPT THERAPEUTICS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

How we classify Corcept Therapeutics Incorporated's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on CORT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — CORT SEC Filings

More Tools for CORT

CORT Full Stock Analysis CORT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper CORT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the CORT stock analysis page.

CORT Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer